Why peptides · why now
Compare San Antonio providers by verifiable details.
San Antonio sits on top of two unusual concentrations of medical infrastructure. The first is the South Texas Medical Center on the northwest side, which is one of the largest medical complexes in the United States and includes UT Health San Antonio, the Mays Cancer Center, and a dense cluster of endocrinology and primary-care practices. The second is the military medicine ecosystem around Joint Base San Antonio, including the San Antonio Military Medical Center at Fort Sam Houston, which feeds a steady population of active-duty and retired service members into the city's general health-care system. Both populations skew toward early adoption of evidence-based protocols, which is why the city has had a viable concierge longevity market for longer than most outside-Texas observers realize.
In 2023, the FDA placed several named peptides (BPC-157, KPV, TB-500, MOTs-C, and others) into Category 2 of the 503A bulk substances list. This restricts but does not prohibit compounding. On April 16, 2026 a Federal Register notice reopened the nominations process. The Pharmacy Compounding Advisory Committee (PCAC) is scheduled to meet July 23–24, 2026 to review the science and vote on whether those compounds move into Category 1 (clearly compoundable under 503A) or stay in Category 2. Whatever the committee decides, San Antonio providers preparing for that meeting may be in a different position afterward.
Texas has been a steady regulatory environment. The Texas State Board of Pharmacy permits 503A compounding for individual patient prescriptions, and the Texas Medical Board has treated bioidentical hormone work and peptide therapy as practice-of-medicine questions for the physician-patient relationship. San Antonio endocrinology and longevity practices have continued to work with licensed compounding pharmacies through the Category 2 period. Find Peptide Clinics makes that legitimate, licensed lane easy to find. We help you avoid the gray-market storefronts.